About Splicing factor U2AF 65 kDa subunit
Splicing factor U2AF 65 kDa subunit (U2AF2) is a protein
from Homo sapiens identified by UniProt accession
P26368, 475 residues long.
MolForge cross-references it against 0 known binders and
78 disease associations.
Target properties
| Protein name | Splicing factor U2AF 65 kDa subunit |
| UniProt accession | P26368 |
| Gene | U2AF2 |
| Organism | Homo sapiens |
| Length | 475 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (78)
Diseases linked to this target (Open Targets).
- Neurodevelopmental disorder · score 0.58
- Intellectual disability · score 0.46
- acute myeloid leukemia · score 0.36
- neurodegenerative disease · score 0.35
- genetic disorder · score 0.33
- leukodystrophy · score 0.26
- chronic lymphocytic leukemia · score 0.16
- non-small cell lung carcinoma · score 0.08
- neoplasm · score 0.06
- lumbar disc degeneration · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P26368-F1 | alphafold | PREDICTED | 73.21 | — |
Amino-acid sequence (475 residues)
MSDFDEFERQ LNENKQERDK ENRHRKRSHS RSRSRDRKRR SRSRDRRNRD QRSASRDRRR RSKPLTRGAK EEHGGLIRSP RHEKKKKVRK YWDVPPPGFE HITPMQYKAM QAAGQIPATA LLPTMTPDGL AVTPTPVPVV GSQMTRQARR LYVGNIPFGI TEEAMMDFFN AQMRLGGLTQ APGNPVLAVQ INQDKNFAFL EFRSVDETTQ AMAFDGIIFQ GQSLKIRRPH DYQPLPGMSE NPSVYVPGVV STVVPDSAHK LFIGGLPNYL NDDQVKELLT SFGPLKAFNL VKDSATGLSK GYAFCEYVDI NVTDQAIAGL NGMQLGDKKL LVQRASVGAK NATLVSPPST INQTPVTLQV PGLMSSQVQM GGHPTEVLCL MNMVLPEELL DDEEYEEIVE DVRDECSKYG LVKSIEIPRP VDGVEVPGCG KIFVEFTSVF DCQKAMQGLT GRKFANRVVV TKYCDPDSYH RRDFW
Explore Splicing factor U2AF 65 kDa subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets